Compare JAGU & GRDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JAGU | GRDX |
|---|---|---|
| Founded | 2022 | N/A |
| Country | Canada | United Kingdom |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.3M | 28.6M |
| IPO Year | 2025 | 2016 |
| Metric | JAGU | GRDX |
|---|---|---|
| Price | $1.47 | $3.60 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 95.3K | 81.9K |
| Earning Date | 03-27-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 68.67 | 21.95 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.41 | $1.87 |
| 52 Week High | $3.60 | $6.93 |
| Indicator | JAGU | GRDX |
|---|---|---|
| Relative Strength Index (RSI) | 37.77 | 51.96 |
| Support Level | N/A | $2.63 |
| Resistance Level | $1.76 | $3.65 |
| Average True Range (ATR) | 0.11 | 0.34 |
| MACD | -0.01 | 0.08 |
| Stochastic Oscillator | 20.24 | 56.00 |
Jaguar Uranium Corp is a uranium exploration and development company focused on uranium discoveries. The company is a junior miner engaged in uranium exploration. Its portfolio is comprised of two uranium exploration projects in Argentina and one uranium exploration project in Colombia. Its projects include the Berlin Project, the Laguna Project, and the Huemul Project. The company operates in one reportable segment which is the exploration and evaluation of mineral properties.
GridAI Technologies Corp, formerly known as Entero Therapeutics Inc, is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.